- Home
- TCBX vs RIGL Comparison
TCBX vs RIGL Comparison
Compare TCBX & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCBX
- RIGL
- Stock Information
- Founded
- TCBX 2008
- RIGL 1996
- Country
- TCBX United States
- RIGL United States
- Employees
- TCBX N/A
- RIGL N/A
- Industry
- TCBX Banks
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- TCBX Finance
- RIGL Health Care
- Exchange
- TCBX Nasdaq
- RIGL Nasdaq
- Market Cap
- TCBX 481.8M
- RIGL 537.6M
- IPO Year
- TCBX 2021
- RIGL 2000
- Fundamental
- Price
- TCBX $38.35
- RIGL $51.48
- Analyst Decision
- TCBX Hold
- RIGL Strong Buy
- Analyst Count
- TCBX 4
- RIGL 5
- Target Price
- TCBX $41.67
- RIGL $43.20
- AVG Volume (30 Days)
- TCBX 54.4K
- RIGL 774.9K
- Earning Date
- TCBX 10-22-2025
- RIGL 11-04-2025
- Dividend Yield
- TCBX N/A
- RIGL N/A
- EPS Growth
- TCBX 38.90
- RIGL 2698.26
- EPS
- TCBX 3.56
- RIGL 6.20
- Revenue
- TCBX $192,224,000.00
- RIGL $282,076,000.00
- Revenue This Year
- TCBX $24.66
- RIGL $59.93
- Revenue Next Year
- TCBX $17.56
- RIGL N/A
- P/E Ratio
- TCBX $10.77
- RIGL $8.22
- Revenue Growth
- TCBX 20.96
- RIGL 79.13
- 52 Week Low
- TCBX $25.17
- RIGL $14.63
- 52 Week High
- TCBX $41.25
- RIGL $51.73
- Technical
- Relative Strength Index (RSI)
- TCBX 55.70
- RIGL 73.90
- Support Level
- TCBX $36.00
- RIGL $34.00
- Resistance Level
- TCBX $37.69
- RIGL $50.23
- Average True Range (ATR)
- TCBX 1.06
- RIGL 3.08
- MACD
- TCBX 0.20
- RIGL 1.13
- Stochastic Oscillator
- TCBX 79.33
- RIGL 96.45
About TCBX Third Coast Bancshares Inc.
Third Coast Bancshares Inc is a bank holding company. It focuses on providing commercial banking solutions to small and medium-sized businesses and professionals with operations in its markets. The bank operates eleven branches in the Greater Houston, Dallas-Fort Worth, and Austin-San Antonio markets, and one branch in Detroit, Texas. The company operates through one segment, community banking, It generates the majority of its revenue from interest on loans, customer service, and loan fees.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.